Regulatory compliance – Page 37

Change impact not assessed during system upgrades – CAPA and revalidation strategy

Assessing Change Impact During System Upgrades: A Comprehensive CAPA and Revalidation Playbook In the highly regulated pharmaceutical environment, staying compliant with GMP regulations is essential. However, system upgrades can often…

Record retention failures during validation lifecycle – preventing repeat Part 11 findings

Addressing Record Retention Issues During the Validation Lifecycle to Prevent Part 11 Findings Record retention failures represent a critical threat in pharmaceutical manufacturing, particularly during the validation lifecycle of Electronic…

Inadequate worst-case selection during inspection readiness – regulatory deficiency risk

Addressing Inadequate Worst-Case Selection During Inspection Readiness: A Practical Playbook In the pharmaceutical manufacturing landscape, the pressure of regulatory compliance and inspection readiness is ever-growing. One common shortfall observed during…

Hybrid paper-electronic workflows uncontrolled during compliance audit – CAPA and revalidation strategy

Strategies for Managing Uncontrolled Hybrid Paper-Electronic Workflows During Compliance Audits In the evolving landscape of pharmaceutical manufacturing, the integration of hybrid paper-electronic workflows has become a common practice. While these…

CSV compliance weak during lifecycle management – preventing repeat validation findings

Strengthening CSV Compliance Throughout the Lifecycle to Prevent Validation Issues As pharmaceutical organizations strive to maintain GMP compliance, they often face challenges related to Computerized System Validation (CSV). Regular deficiencies…

Archival process non-compliant during routine studies – CAPA for GLP system gaps

Managing Non-Compliance in Archival Processes During Routine Studies In the fast-paced environment of pharmaceutical manufacturing and laboratory studies, any lapse in compliance can lead to significant risks and regulatory scrutiny.…

Electronic signatures misused during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Electronic Signature Misuse Throughout the Validation Lifecycle In pharmaceutical manufacturing and quality control, the implementation of electronic signatures holds significant potential for operational efficiency and compliance. However, misuse of…

Requalification overdue during site expansion – risk-based validation alignment

Managing Requalification During Site Expansion: A Risk-Based Validation Approach In the dynamic landscape of pharmaceutical manufacturing, the process of site expansion presents unique challenges, particularly when it comes to maintaining…

Hybrid paper-electronic workflows uncontrolled during validation lifecycle – CAPA and revalidation strategy

Addressing Uncontrolled Hybrid Paper-Electronic Workflows in Validation Lifecycle In today’s pharmaceutical landscape, hybrid paper-electronic workflows present significant challenges, particularly in maintaining compliance during the validation lifecycle. As organizations strive for…

Tag: Regulatory compliance